Semiconductor Test Equipment

Here's how I'm framing the next two quarters from the CFO chair. The first assumption is that the AI-test intensity story keeps playing out. Every advanced packaging line and every HBM stack needs more test sockets per wafer, and our customer mix is tilting heavily toward those higher-pin-count, higher-mix platforms. That's why I'm holding gross margin in the 59–60% zone even after the 60.9% peak in Q1 — mix should stay favorable, but I don't want to extrapolate a one-quarter print. Second assumption: revenue moderates sequentially into Q2 then re-accelerates into Q3 as customers burn through the test capacity they locked in earlier and prep for fall builds. I have Q2 down a touch from Q1's record, then Q3 climbing back to a fresh high. Net income naturally follows the same arc, with operating leverage still doing real work because fixed costs in the test cell business stay relatively contained. The top risk I keep staring at is cyclicality. ATE is the last gate before silicon ships, which is great when wafer starts are surging and terrifying when they're not. Hyperscaler capex digestion, a pause in advanced-node ramps, or a sudden unwind in memory pricing could compress utilization and margin fast. We're also levered to a handful of advanced-packaging customers, so any mix shift hits both top line and gross profit in the same quarter. I'd rather forecast conservatively and surprise up than get caught extrapolating the cycle top.